Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
3SBio, Inc.
AMAG Pharmaceuticals, Inc. and 3SBio, Inc. Announce Strategic Partnership to Develop and Commercialize Ferumoxytol in China
June 13th, 2008
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) and 3SBio, Inc. (NASDAQ:SSRX), a leading Chinese biotechnology company, announced the signing of a development and commercialization agreement for ferumoxytol, an intravenous iron replacement therapeutic agent being developed to treat iron deficiency anemia in chronic kidney disease (CKD) patients. "This is an exciting first step towards expanding the potential use of ferumoxytol outside the United States. China represents a large and rapidly growing market opportunity as there are approximately 12 million Stage 3 and 4 CKD patients(1), and over 91,000 patients on dialysis in China(2)," stated Brian J.G. Pereira, MD, President...
Source: Health Business Week (2008-06-13)
|
